PapersPMID:21311504
Vitamin D3 supplementation for 16 weeks improves flow-mediated dilation in overweight African-American adults.
- findings
- 2
- compound
- 1
- endpoints
- 2
calciol- Study, every finding
- RCT · 4 months
- Dose studied, every finding
- 60,000 IU oral vitamin D3 every 4 weeks at supervised visits, 16 weeks, against identical placebo
- Population, every finding
- Apparently healthy African American men and women aged 19 to 50 with no overt cardiovascular, pulmonary or metabolic disease; completers with FMD testing
What moved
How to read these marks →- Increases flow-mediated dilation
moderate
“Simple main effects further identified a significantly greater FMD in the vitamin D group compared to the placebo group at 16 weeks.”
- Increases serum 25-hydroxyvitamin D concentration
moderatereplicated ×35
“A Treatment × Time interaction (F1,41 = 66.5; p<0.001) was detected such that a robust increase in 25(OH)D was observed in the vitamin D group, whereas the placebo group exhibited a slight increase in 25(OH)D.”
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Apparently healthy overweight African American men and women aged 19-50 years; oral vitamin D3 60,000 IU every 4 weeks (form: vitamin D3, cholecalciferol) vs placebo
- Participants
- 45
- Comparator
- placebo
- Duration
- 112 days
- Endpoints measured
- 27